InvestorsHub Logo
Followers 9
Posts 402
Boards Moderated 0
Alias Born 04/22/2013

Re: None

Saturday, 08/18/2018 8:19:37 PM

Saturday, August 18, 2018 8:19:37 PM

Post# of 233035
Took a peek at Theratechnolgies web site. They announced 2Q earnings on July 5th. Total revenue was $12.3 million- Lions share was Egrifta that raked in $11,100,000 and the first thirty days of Trogarzo ( Ibalizumab) saw $1,200,000 in sales.

Egrifta was made to fight/reduce the excess abdominal fat ( VAT) that is a problematic/dangerous side effect of ART treatment. Most interesting point found was these patients administer a DAILY subcutaneous powder injection in abdominal wall - So for those that think a weekly injection could be a deterrent to treatment, certainly doesn't appear to be the case.

Thera has a short instructional video on their site illustrating how simple, quick & easy the injection is to administer-
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News